Trial Profile

Evaluation of the Efficacy of MaaT013 As Salvage Therapy in Acute GVHD Patients with Gastrointestinal Involvement, Refractory to Ruxolitinib; a Multi-center Open-label Phase III Trial.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Mar 2026 According to a MaaT Pharma media release, data from this study will be presented at the 2026 EBMT Annual Meeting, taking place March 22-25, 2026 in Madrid, Spain.
09 Mar 2026 According to a MaaT Pharma media release, data from this study will be presented at the 2026 EBMT Annual Meeting, taking place March 22-25, 2026 in Madrid, Spain.
08 Dec 2025 According to MaaT Pharma media release, data from the trial were presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition currently taking place in Orlando, Florida, USA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com